Why did Forever 21 go out of business? What to know in Michigan
Forever 21 is gone forever in Michigan and nationwide as the chain's bankruptcy moves forward.
As malls and the once-popular fast-fashion retailer have declined, Forever 21 struggled financially amid global competition from online retailers, leading the company to file Chapter 11 bankruptcy and close all U.S. stores this spring.
In Michigan, the nine stores at malls across the state were set to have closed permanently as of May 1.
"On behalf of the Company, I'd like to express our deep appreciation for the hard work of our dedicated employees and their commitment to our customers. We are also grateful for the many years of support from our partners and our loyal customers, who have allowed us to serve as a fashion industry leader and go-to retailer for generations," Chief Financial Officer Brad Sell said in the bankruptcy announcement.
Here's what to know.
When did Forever 21 stores close?
All Michigan Forever 21 stores were set to close by May 1, 2025, according to court documents.
The Forever 21 website was still up as of Monday, May 5.
What is Forever 21?
Forever 21 is a fast-fashion retail chain selling men's and women's clothing, accessories and more.
Will Forever 21 continue to honor gift cards?
Forever 21 stopped accepting gift cards and store credit on April 15, USA TODAY reported.
Will Forever 21 offer refunds?
Refunds and exchanges are also no longer available.
Where were Michigan's Forever 21 stores?
Forever 21 operated the following nine stores in Michigan:
Briarwood Mall in Ann Arbor: 602 Briarwood Circle, D101A
Great Lakes Crossing Outlets in Auburn Hills: 4160 Baldwin Road
The Mall at Partridge Creek in Clinton Township: 17360 Hall Road No. 191
Fairlane Town Center in Dearborn: 18900 Michigan Ave.
Woodland Mall in Grand Rapids: 3195 28th St. SE
Twelve Oaks Mall in Novi: 27434 Novi Road
The Crossroads Mall in Portage: 6650 S. Westnedge Ave., No. 139
Southland Center in Taylor: 23000 Eureka Road Space, No. 1360
Oakland Mall in Troy: 460 W. 14 Mile Road
When did Forever 21 file for bankruptcy?
Forever 21 filed for Chapter 11 bankruptcy March 16, 2025.
Why did Forever 21 file for bankruptcy?
The company had been facing financial challenges amid competition from Chinese online discount retailers such as Shein and Temu.
Forever 21 had previously announced store closings, the closure of its Los Angeles headquarters and layoffs of more than 350 employees, USA TODAY reported.
USA TODAY contributed.
Contact Jenna Prestininzi: jprestininzi@freepress.com.
This article originally appeared on Detroit Free Press: Forever 21 gone forever in Michigan as stores close
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
FAW Toyota launches new bZ5 electric SUV
FAW Toyota Motor Company, one of Toyota's main Chinese joint ventures, officially launched its new competitively-priced bZ5 battery-powered SUV on the local market, as the Japanese automaker looks to strengthen its foothold in China's fast-expanding new energy vehicle (NEV) market. The new bZ5 is available initially in four main variants, the 550 Joy, 550 Pro, 550 Pro Smart Drive and the 630 Pro, offering varying levels of equipment and trim, and with prices ranging between CNY 129,800 and CNY 159,800 yuan (US$ 18,100-US$ 22,300), inclusive of manufacturer incentives. The bZ5 550 models are powered by 200 kW motors, with their standard battery pack offering a maximum range of 550 km on a single charge. The come with features such as 16-inch central touchscreen, 5G connectivity, and AI-powered voice control. The 630 Pro model has an extended range of 630 km. The bZ5 range is designed to compete with the Tesla Model Y, China's best-selling battery-powered SUV, and is priced significantly lower than the Model Y's starting price of CNY263,500 while offering a similar range. "FAW Toyota launches new bZ5 electric SUV" was originally created and published by Just Auto, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
12 minutes ago
- Yahoo
BYD Introduces Most Affordable EV Model in the United Kingdom
BYD Company Limited BYDDY, an EV manufacturer in China, has introduced its most affordable model in the United Kingdom as part of its broader strategy to surpass Tesla as the world's leading electric vehicle manufacturer. The newly launched Dolphin Surf is the European version of BYD's top-selling Chinese model, the Seagull, which recently saw its price drop to just $7,800 in China following further the China Automobile Manufacturers Association didn't name BYD directly, it recently cautioned that ongoing price reductions are fueling fears of a renewed price war in the Chinese EV market. BYD's Dolphin Surf, priced from around $25,000, appears to be extending that pricing pressure into the United Kingdom, BYD outpaced Tesla in monthly vehicle registrations last month, selling 3,025 vehicles compared to Tesla's 2,016 units, and is on track to challenge Tesla's full-year performance. In April, BYD also overtook Tesla in European registrations for the first time, even before the Dolphin Surf entered the the UK's least expensive EV is the Dacia Spring, starting at $20,000 with a WLTP range of 140 miles. BYD's base Dolphin Surf 'Active' variant offers a 203-mile range, while the 'Boost' version extends that to 305 miles and starts at $30,000. Both models come equipped with premium features, such as a 10.1-inch rotatable touchscreen and smart driving functions. Although EVs already tend to be cheaper to own than petrol cars, the emergence of compact, low-cost EVs is seen as key to attracting more budget-conscious buyers. BYD's rapid growth in Europe continues despite the European Union imposing 17.4% tariffs on its vehicles due to concerns over Chinese government subsidies. The United Kingdom, however, has not imposed such tariffs, making it an attractive and increasingly important market for BYD. BYD has a Zacks Rank #5 (Strong Sell) at better-ranked stocks in the auto space are CarGurus, Inc. CARG, Strattec Security Corporation STRT and Michelin MGDDY, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today's Zacks #1 Rank stocks Zacks Consensus Estimate for CARG's 2025 sales and earnings implies year-over-year growth of 4.96% and 25%, respectively. EPS estimates for 2025 and 2026 have improved 30 cents and 44 cents, respectively, in the past 60 Zacks Consensus Estimate for STRT's fiscal 2025 sales and earnings implies year-over-year growth of 3.49% and 8.11%, respectively. EPS estimates for fiscal 2025 and 2026 have improved 73 cents and 91 cents, respectively, in the past 60 Zacks Consensus Estimate for MGDDY's 2025 sales and earnings implies year-over-year growth of 1.69% and 37.76%, respectively. EPS estimates for 2025 have improved a penny in the past 30 days. EPS estimates for 2025 have improved 3 cents in the past seven days. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Strattec Security Corporation (STRT) : Free Stock Analysis Report Michelin (MGDDY) : Free Stock Analysis Report CarGurus, Inc. (CARG) : Free Stock Analysis Report Byd Co., Ltd. (BYDDY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Gene Solutions and Shenzhen USK Bioscience Forge Strategic Partnership to Establish Next-Generation Sequencing Laboratory in Southern China
SINGAPORE, June 14, 2025 /PRNewswire/ -- Gene Solutions, a leading multinational biotechnology company and Shenzhen USK Bioscience Co., Ltd. (USKBio), a prominent innovator in molecular diagnostics, have entered a strategic partnership through a Memorandum of Understanding (MOU). The landmark agreement paves the way for the establishment of a state-of-the-art next generation sequencing (NGS) laboratory in southern China, advancing localized oncology diagnostics. The collaboration will leverage USKBio's existing infrastructure, and Gene Solutions' advanced next-generation AI & genomics capabilities to jointly establish a next-generation sequencing (NGS) laboratory. The lab will focus on accelerating access to early cancer detection and molecular residual disease (MRD) monitoring using AI-powered circulating tumor DNA (ctDNA) technologies, tailored to address the unique clinical needs of southern China's healthcare landscape. USKBio brings extensive expertise in Polymerase Chain Reaction (PCR)-based In Vitro Diagnostics (IVD) and Good Manufacturing Practice (GMP)-certified production capabilities. Gene Solutions contributes its leadership in NGS-based oncology applications, highlighted by its groundbreaking SPOT-MAS test — Asia's first clinically validated multi-cancer early detection (MCED) assay, validated through a prospective study of 9,024 participants. Additionally, Gene Solutions recently published a real-world MRD study involving 623 patients across six cancer types—lung, colorectal, breast, gastric, liver, and ovarian—demonstrating the clinical utility of ctDNA for monitoring treatment response and assessing recurrence risk. This partnership will focus on localizing and validating these cutting-edge technologies for the Chinese market while fostering joint R&D and production of advanced IVD medical devices. This alliance represents a major step forward in delivering accessible, high-impact, personalized cancer diagnostics to a broader population in China. "This partnership with USKBio allows us to move quickly in establishing a high-impact oncology hub in southern China," said Dr. Nguyen Hoai Nghia, CEO and Co-founder at Gene Solutions. "Together, we aim to bring early, accurate, and scalable cancer screening and diagnostics to more patients, ultimately improving cancer outcomes." "Gene Solutions and USKBio are highly complementary in their core technologies, regional markets, and business models." said Dr. Yu Dehua, CEO at USKbio. "This strategic collaboration will leverage both parties' strengths, creating strong synergies to deliver greater benefits to cancer patients across the Asia region." The partnership also includes technology transfer, technical training, and joint commercialization efforts to ensure rapid deployment and widespread adoption of these advanced genomic tools. About Shenzhen USKBio Founded in August 2015, Shenzhen USKBio is a national high-tech biological enterprise established by leading Chinese and American scientists and entrepreneurs. Specializing in in vitro molecular diagnostics, USKBio integrates R&D, production, marketing, and medical testing services, with a robust presence in IVD reagents, diagnostic instruments, and testing services. Leveraging proprietary technologies such as Udx-PCR and Udx-MSP, the company offers innovative solutions for early cancer screening, precision diagnosis, and companion diagnostics. With over 36 authorized patents and collaborations across top hospitals and testing institutions in China, USKBio is a rising leader in the global molecular diagnostics industry, dedicated to advancing precision medicine. About Gene Solutions Gene Solutions is a leading multinational biotechnology company headquartered in Asia, pioneering the integration of advanced AI and circulating tumor DNA (ctDNA) technologies to deliver innovative solutions across the cancer care continuum. Recognized for its proprietary research and CAP-accredited laboratories, the company combines multi-dimensional genomics with AI-driven analytics to transform oncology—from early detection to real-time treatment monitoring. With a strong regional presence and a commitment to empowering access to precision medicine, Gene Solutions is shaping the future of cancer diagnostics and personalized care across the Asia-Pacific. Explore more information at: View original content to download multimedia: SOURCE Gene Solutions Genomics Pte Ltd Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
